Item 1.02. Termination of a Material Definitive Agreement.

On March 12, 2009, Neurobiological Technologies, Inc. (the "Company") notified Abbott Laboratories ("Abbott") of its intention to terminate the License Agreement, dated as of March 29, 2002, between the Company (as successor of Empire Pharmaceuticals, Inc.) and Abbott, as amended (the "Agreement"), effective as of June 10, 2009. Under the Agreement, Abbott granted the Company an exclusive worldwide license for all human therapeutic indications for Viprinex (ancrod) and the Company had an obligation to use commercially reasonable efforts to develop Viprinex for the treatment of acute ischemic stroke. No early termination penalties were incurred by the Company in connection with the termination of the Agreement. Pursuant to the terms of the Agreement, the Company intends to return all materials, studies and information relating to Viprinex to Abbott upon receipt of the delivery instructions from Abbott.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On March 13, 2009, the Compensation Committee of the Board of Directors of the Company approved the payment of compensation of $25,000 per month to William A. Fletcher for his services as the Company's Acting Chief Executive Officer, effective retroactive to his appointment to this office on January 30, 2009.